Collexis Holdings, Inc. Acquires SyynX Solutions GmbH, Expands Application Portfolio

SyynX Solutions GmbHCollexis Holdings, Inc. (OTCBB: CLXS) has acquired its long-time development partner, SyynX Solutions, a privately-held software company based in Cologne, Germany. SyynX Solutions will remain as a subsidiary of Collexis Holdings – with the amendment "a Collexis company", and will take care of existing customers and drive Collexis' business in Europe. The SyynX management team will be part of the Collexis Holdings management team.

The joint history of both companies:
SyynX and Collexis were founded at the same time in 1999 as offspring of an EU funded research project. SyynX started then to develop parts of the fingerprint technology for Collexis. In less than ten years Collexis has become the market leader of knowledge applications especially for the scientific context. In 2005 Collexis moved its global headquarters to Columbia, South Carolina and introduced the SyynX applications to the American market. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). The applications developed by SyynX are based on the patented Collexis fingerprint technology, i.e. the Knowledge or Protein Dashboard, the search platform Mediator and the Social Networking platform for the Life Sciences with more than 1M of pre-populated expert profiles. The later was recently jointly developed with Collexis and will be launched at the beginning of 2008.

"After working together with the Collexis team for several years, the SyynX team is more than excited about bringing the two companies together," says Christian Herzog, MD, CEO of SyynX Solutions. "The Collexis Fingerprint core technology, combined with the applications built by SyynX, will provide a great advantage to existing customers, as well as future ones."

Bill Kirkland, CEO of Collexis. "The SyynX software component is an ideal strategic complement to our existing capabilities as the market leader in high-definition search and discovery solutions. Our comprehensive offerings address a growing market trend, as scientists are increasingly recognizing the essential role that informatics, database and workflow solutions play in more effectively managing research programs and driving higher productivity. We believe that the acquisition of SyynX will position Collexis as a global leader in providing these solutions and our value proposition to clients will be stronger as a result."

Related news article:

About Collexis Holdings, Inc.
Collexis Holdings, Inc., a leading developer of High Definition Search and Discovery software since 1999, is headquartered in Columbia, South Carolina (USA) with two subsidiaries; Collexis Inc. in Columbia, South Carolina, USA and Collexis, B.V. in Geldermalsen, The Netherlands. Collexis proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, websites, e-mails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis shares of common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, please visit www.collexis.com.

About SyynX Solutions GmbH
SyynX Solutions GmbH is a German software company which focuses on text mining based applications for the areas of life science and health care. Collexis and SyynX are already co-operating closely since almost ten years on the technical and commercial level. The SyynX applications based on the Collexis fingerprint technology are used by customers like universities, pharmaceutical and biotech companies around the world. The text mining applications like the SyynX Knowledge Dashboard helps the user to analyze large text corpora without applying standard search approaches and provides him automatically with expert profiles, trends and knowledge discovery routines. For more information please visit www.syynx.de.

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...